Ovizio Launches In-Line Suspension Cell-Monitoring Microscope

Ovizio Imaging System has launched its iLine F, an in-line suspension cell-monitoring microscope that uses a quantitative imaging technique based on Differential Digital Holographic Microscopy. The suspension cell-monitoring microscope monitors cell viability and cell density in real-time as well as recording aggregate data and up to 16 morphologic parameters, according to the company.
 
Ovizio executives claim the iLineF reduces costs and changes the way suspension cells are monitored, counted and analyzed. The automated technology means there is no need for manual operation; operators can focus on other projects while the iLine F monitors the culture. The technology also offers increased insight into the cell culture process by continuously collecting quantitative data providing reproducible, reliable results, bigwigs noted in a news release.
 
The iLine F is an in-line, label free and non-invasive solution with no sampling, no staining and no toxic waste. The technology is designed for bioreactor grown suspension cells. The iLine F is connected to a bioreactor via an innovative disposable fluidics probe, avoiding sample consumption and reducing the risk of contamination.

“The iLine F combines the best of both worlds, utilizing Applikon’s bioprocess knowledge and Ovizio’s quantitative microscopy expertise,” said Philip Mathuis, CEO of Ovizio. “It offers a solution for cell culture applications, as users benefit from its unique feature: a continuous real-time measurement that streamlines the cell-monitoring process.”
 
The launch of the iLine F microscope is the result of a long-term global marketing and distribution agreement between Ovizio and Applikon Biotechnology. This agreement includes a global business development plan and covers customer support, maintenance and additional services.
 
The addition of the iLine F to the Ovizio product line will secure additional revenue and open up new market opportunities in suspension cell monitoring, executives said. Ovizio also benefits from the Applikon partnership, gaining access to its global distribution network and international customer base, Applikon officials added.
 
“Our partnership with Ovizio will allow Applikon to bring cutting edge bioprocessing technology to the market and to our existing clients,” said Erik Kakes, co-owner and international sales and marketing director at Applikon. “It also gives us a new way to approach scientists who are continuously looking to optimize their processes and need a solution for cell culture monitoring.”
 
Ovizio is a Belgian company developing quantitative microscopy solutions for life sciences applications. Ovizio’s microscopes offer label-free and non-invasive tools for real-time 3-D imaging of living cells.

Applikon is a privately owned Dutch company developing, manufacturing and supplying bioreactor systems for both research and production use.